Navigation Links
BioMS Medical Announces Third Quarter 2008 Results
Date:11/6/2008

the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide (MBP8298) in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Corporation's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Corporation's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 The Pittcon Organizing Committee ... Food Safety Tech , an e-Journal and producer of ... agreement for the second year for the co-location of Food ... The partnership provides that the registration fee to attend the ...
(Date:1/15/2014)... IL (PRWEB) January 15, 2014 Look ... find hard-working items for the lab, from fluid handling ... Guaranteed-in-Stock (GIS)—ready to ship when you order. , ... Peristaltic Pumps , from the L/S® model for precise ...
(Date:1/15/2014)... SAN JOSE, California , January 15, 2014 ... conjugates for cancer, today announced the appointment of Thomas C ... has over 20 years, development experience gained in the biotechnology ... "I am delighted to welcome Tom at this ...
(Date:1/15/2014)... This webinar will focus on EMA and ... in biosimilars. , Regulatory frameworks are evolving many countries ... the complex nature of biopharmaceuticals makes the demonstration of ... challenging. Based on the specific aspects of biosimilar drug ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2
... June 25 Lixte,Biotechnology Holdings (OTC Bulletin Board: ... Disorders and Stroke (NINDS), National,Institutes of Health (NIH) ... and Development Agreement (CRADA) to develop,drugs for the ... March,2006 was extended through September 2009., Dr. ...
... titled “Avanta AC™ Advanced Ceramics Solutions as ... white paper outlines the challenges in manufacturing ... as well as the advantages of SACHEM’s ... are critical to a variety of leading ...
... (OTCBB:BTIM) and BioTime’s wholly-owned subsidiary Embryome Sciences, ... agreement with International Stem Cell Corporation (OTCBB:ISCO) ... (Lifeline) to jointly produce and distribute hundreds ... cell lines, along with corresponding data and ...
Cached Biology Technology:Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs 2Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs 3 SACHEM Launches New Products for High Purity Advanced Ceramic Powders : Avanta AC™ Advanced Ceramics Solutions Offer Unique Advantages over Inorganic Bases in the Manufacture of Advanced Ceramic Nanoparticles 2 BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use 2 BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use 3 BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use 4 BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use 5
(Date:4/18/2014)... adds a twist to the story of how barnyard chickens ... 21 in the journal Proceedings of the National Academy ... chickens that lived 200-2300 years ago in Europe, researchers report ... have looked far different from the chickens we know today. ... associate with modern domestic chickens -- such as their yellowish ...
(Date:4/17/2014)... Ill. A drug under clinical trials to treat ... broad-spectrum drugs that act against various bacteria, fungal infections ... by University of Illinois chemists and collaborators. , Led ... team determined the different ways the drug SQ109 attacks ... to target other pathogens from yeast to malaria ...
(Date:4/17/2014)... suggests that fish consumption advisories for expecting mothers ... contaminants like persistent organic pollutants (POPs). , ... including University of Toronto Scarborough PhD student Matt ... different levels of environmental contamination, a mother,s compliance ... the body influenced exposure in her children. , ...
Breaking Biology News(10 mins):Ancient DNA offers clues to how barnyard chickens came to be 2Multitarget TB drug could treat other diseases, evade resistance 2Fish consumption advisories fail to cover all types of contaminants 2
... sp. DN1 , which may prove to be ... snow fields of the Rocky Mountains. Research examining this new ... DN1 was found to grow at temperatures approaching freezing ... sp. DN1 produces the highest quantity of lipids when ...
... into two species, the one-humped dromedary and the two-humped ... camels are precious in desert regions throughout the world. ... makes them ideally suited for transportation. In addition, camels ... without food and water. Despite the extremely arid conditions, ...
... AURORA, Colo. (May 27, 2013) A new study ... caused a significant spike in the number of young ... and beverages. "We have seen an increase in ... of drugs laws in Colorado," said George Wang, MD, ...
Cached Biology News:Decoding the genome of the camel 2Surge in children accidentally eating marijuana-laced foods 2Surge in children accidentally eating marijuana-laced foods 3
Desmosomal Protein Immunogen: Full length, native protein purified from human epidermal keratins. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Mouse monoclonal [SPM217] to Secretory Component Glycoprotein ( Abpromise for all tested applications)....
Mouse monoclonal [3G8] to MDMA ( Abpromise for all tested applications)....
Shh Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Biology Products: